高俊耀



低分子肝素钙治疗肺心病合并呼吸衰竭的临床分析

高俊耀

【摘要】目的 分析肺心病合并呼吸衰竭采用低分子肝素钙治疗的疗效。方法 研究2015年1～12月，纳入对象肺心病合并呼吸衰竭有65例，随机分组。31例施行常规疗法，进入对照组；34例应用低分子肝素钙，进入观察组，组间比较分析。结果 两组中观察组PaO2和PaCO2改善明显，治疗有效率更高，差异具有统计学意义（P＜0．05）。结论 低分子肝素钙对肺心病合并呼吸衰竭治疗效果较好。

【关键词】肺心病；呼吸衰竭；低分子肝素钙；治疗

Objective Low-molecular-weight heparin calcium effect in treatment of pulmonary heart disease complicated with respiratory failure is to be studied．Methods Chose 65 patients of pulmonary heart disease complicated with respiratory failure who are treated in hospital from January 2015 to December 2015 and separated them into two groups at random，31 patients in control group were given conventional treatment，while another 34 patients in study group were given low-molecular-weight heparin calcium treatment and then compared treatment effects between two groups． Results Patients’diameters of PaO2and PaCO2in study group were improved much more favorable and treatment efficacy was much higher compared to counterparts in control group，there was a differential between two groups and such a differential had statistic value（P＜0．05）． Conclusion Low-molecularweight heparin calcium in treatment of pulmonary heart disease complicated with respiratory failure．

【Key words】 Pulmonary heart disease，Respiratory failure，Low-molecular-weight heparin calcium，Treatment

肺心病发生与肺血管疾病、肺疾病、支气管疾病及胸廓运动障碍性疾病等相关，缓解期患者有呼吸困难、慢性咳嗽、乏力、咳痰和气急等症状，体检见肺气肿征；急性加重期病患主要有呼吸衰竭症状，不伴或伴心力衰竭［1］。此文研究2015年1～12月纳入对象肺心病合并呼吸衰竭有65例，总结低分子肝素钙治疗疗效，具体见下。

1 资料和方法

1.1 一般资料

研究2015年1～12月，纳入对象肺心病合并呼吸衰竭有65例，随机分组。31例施行常规疗法，进入对照组，年龄33～79岁，平均（51.78±8.45）岁，女患者10例，男患者21例，肺心病病史2～13年，平均（8.44±2.30）年，心功能分级：Ⅳ级11例，Ⅲ级20例。34例应用低分子肝素钙，进入观察组，年龄33～80岁，平均（51.62±8.23）岁，女患者有11例，23例是男患者，肺心病病史2～13.8年，平均（8.21±2.48）年，心功能分级：Ⅳ级12例，Ⅲ级22例。两组排除肾脏癌病、肺梗死、糖尿病及代谢酸中毒等疾病。组间差异不具有统计学意义（P＞0.05）。

1.2 方法

1.2.1 对照组 对病患施行强心、吸氧、解痉、抗感染和利尿等治疗。

1.2.2 观察组 低分子肝素钙，2次/d，肌肉注射，80 IU/kg，每隔12 h/次，1疗程7 d。……